Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines.

Since 2002, Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders. The company is advancing a diversified portfolio of clinical candidates across Oncology and Inflammation & Autoimmunity.

Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For more information, you may visit https://www.incytebiosciences.uk/

If you are a UK healthcare professional, you may visit https://contact.virtualincyte.com to provide consent to be sent further information relevant to your clinical practice.

UK/CORP/NP/24/0001 April 2024